Cargando…
Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy
BACKGROUND: Several cytokines including transforming growth factor (TGF)-β1 have been suggested to be involved in the pathogenesis of fibrosis in chronic hepatitis C. We examined the changes of TGF-β1 serum levels and their predictive value in patients with chronic hepatitis C under antiviral therap...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hellenic Society of Gastroenterology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700851/ https://www.ncbi.nlm.nih.gov/pubmed/26752952 |
_version_ | 1782408389638225920 |
---|---|
author | Kotsiri, Ioanna Hadziyannis, Emilia Georgiou, Anastasia Papageorgiou, Maria-Vasiliki Vlachogiannakos, Ioannis Papatheodoridis, George |
author_facet | Kotsiri, Ioanna Hadziyannis, Emilia Georgiou, Anastasia Papageorgiou, Maria-Vasiliki Vlachogiannakos, Ioannis Papatheodoridis, George |
author_sort | Kotsiri, Ioanna |
collection | PubMed |
description | BACKGROUND: Several cytokines including transforming growth factor (TGF)-β1 have been suggested to be involved in the pathogenesis of fibrosis in chronic hepatitis C. We examined the changes of TGF-β1 serum levels and their predictive value in patients with chronic hepatitis C under antiviral therapy. METHODS: We included 84 patients with chronic hepatitis C who were treated with pegylated interferon-α and ribavirin between 2008 and 2009. Treatment was given for 24-48 weeks depending on HCV genotype. Serum TGF-β1 levels were measured by an ELISA assay at baseline, at the end of therapy (EOT), and at 6 months after the EOT. Liver fibrosis was evaluated by transient elastography. RESULTS: Of the 84 patients, 76.2% achieved sustained virological response (SVR), 8.3% responded at the EOT but relapsed during post-therapy follow up (RR) and 15.5% had no response (NR). In all patients, mean TGF-β1 levels were 16,980 pg/mL at baseline and decreased significantly at EOT (12,041 pg/mL) and at 6 months of post-treatment follow up (13,254 pg/mL) (P≤0.001). In particular, mean TGF-β1 levels decreased significantly from baseline to EOT and to six months of post-treatment follow up in patients with SVR and numerically but not significantly in patients with RR or NR. TGF-β1 levels were not associated with the severity of liver stiffness estimated by transient elastography. CONCLUSION: Our data show that TGF-β1 serum levels decrease significantly at the EOT and remain decreased 6 months after the EOT mostly in chronic hepatitis C patients who achieve SVR after pegylated interferon-α and ribavirin combination treatment. |
format | Online Article Text |
id | pubmed-4700851 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hellenic Society of Gastroenterology |
record_format | MEDLINE/PubMed |
spelling | pubmed-47008512016-01-08 Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy Kotsiri, Ioanna Hadziyannis, Emilia Georgiou, Anastasia Papageorgiou, Maria-Vasiliki Vlachogiannakos, Ioannis Papatheodoridis, George Ann Gastroenterol Original Article BACKGROUND: Several cytokines including transforming growth factor (TGF)-β1 have been suggested to be involved in the pathogenesis of fibrosis in chronic hepatitis C. We examined the changes of TGF-β1 serum levels and their predictive value in patients with chronic hepatitis C under antiviral therapy. METHODS: We included 84 patients with chronic hepatitis C who were treated with pegylated interferon-α and ribavirin between 2008 and 2009. Treatment was given for 24-48 weeks depending on HCV genotype. Serum TGF-β1 levels were measured by an ELISA assay at baseline, at the end of therapy (EOT), and at 6 months after the EOT. Liver fibrosis was evaluated by transient elastography. RESULTS: Of the 84 patients, 76.2% achieved sustained virological response (SVR), 8.3% responded at the EOT but relapsed during post-therapy follow up (RR) and 15.5% had no response (NR). In all patients, mean TGF-β1 levels were 16,980 pg/mL at baseline and decreased significantly at EOT (12,041 pg/mL) and at 6 months of post-treatment follow up (13,254 pg/mL) (P≤0.001). In particular, mean TGF-β1 levels decreased significantly from baseline to EOT and to six months of post-treatment follow up in patients with SVR and numerically but not significantly in patients with RR or NR. TGF-β1 levels were not associated with the severity of liver stiffness estimated by transient elastography. CONCLUSION: Our data show that TGF-β1 serum levels decrease significantly at the EOT and remain decreased 6 months after the EOT mostly in chronic hepatitis C patients who achieve SVR after pegylated interferon-α and ribavirin combination treatment. Hellenic Society of Gastroenterology 2016 /pmc/articles/PMC4700851/ /pubmed/26752952 Text en Copyright: © Hellenic Society of Gastroenterology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kotsiri, Ioanna Hadziyannis, Emilia Georgiou, Anastasia Papageorgiou, Maria-Vasiliki Vlachogiannakos, Ioannis Papatheodoridis, George Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy |
title | Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy |
title_full | Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy |
title_fullStr | Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy |
title_full_unstemmed | Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy |
title_short | Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy |
title_sort | changes in serum transforming growth factor-β1 levels in chronic hepatitis c patients under antiviral therapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700851/ https://www.ncbi.nlm.nih.gov/pubmed/26752952 |
work_keys_str_mv | AT kotsiriioanna changesinserumtransforminggrowthfactorb1levelsinchronichepatitiscpatientsunderantiviraltherapy AT hadziyannisemilia changesinserumtransforminggrowthfactorb1levelsinchronichepatitiscpatientsunderantiviraltherapy AT georgiouanastasia changesinserumtransforminggrowthfactorb1levelsinchronichepatitiscpatientsunderantiviraltherapy AT papageorgioumariavasiliki changesinserumtransforminggrowthfactorb1levelsinchronichepatitiscpatientsunderantiviraltherapy AT vlachogiannakosioannis changesinserumtransforminggrowthfactorb1levelsinchronichepatitiscpatientsunderantiviraltherapy AT papatheodoridisgeorge changesinserumtransforminggrowthfactorb1levelsinchronichepatitiscpatientsunderantiviraltherapy |